Cat. No.: HY-146548

Anticancer agent 43

Avis client

Based on 1 Customer Validation

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces apoptosis by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.58%
CAS No.: 2470015-35-9
Formule: C₁₄H₉FN₂O₃S₂
Masse moléculaire:336.36

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Anticancer agent 43 Chemical Structure

CAS No.: 2470015-35-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces apoptosis by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage^[1].

IC₅₀ & Target^[1]

Caspase 3

PARP1

Bax

Voir tous les produits spécifiques à Isoform Bcl-2 Family :

Voir tous les produits spécifiques à Isoform Caspase :

Voir tous les produits spécifiques à Isoform PARP :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	9.7 μM Compound: 3a	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	25 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	40.8 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	48.3 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	51.5 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	54.3 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	62.8 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay	[PMID: 34634616]
BALB/3T3	GI₅₀	89.7 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay	[PMID: 34634616]
HaCaT	GI₅₀	98.3 μM Compound: 3a	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HCT-116	GI₅₀	0.8 μM Compound: 3a	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HeLa	GI₅₀	49.3 μM Compound: 3a	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	0.04 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	0.06 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	0.31 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	12.1 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	16.3 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	24.5 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay	[PMID: 34634616]
HepG2	GI₅₀	35.6 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	40.1 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay	[PMID: 34634616]
HepG2	GI₅₀	44.7 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	63.9 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	7.5 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay	[PMID: 34634616]
MCF7	GI₅₀	0.7 μM Compound: 3a	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
THP-1	GI₅₀	62.4 μM Compound: 3a	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
WM793	GI₅₀	80.4 μM Compound: 3a	Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]

In Vitro

Anticancer agent 43 (compound 3a) shows selectivity toward human tumor cells (SI₅₀=28.94)^[1].
Anticancer agent 43 (45 µM, 24 h) induces apoptosis via caspase 3, PARP1 and Bax dependent pathways in HepG2 cells^[1].
Anticancer agent 43 (45 µM, 24 h) shows no effect on the transition of G1/S phases in HepG2 cells^[1].
Anticancer agent 43 (0.7, 45, 55 µM) induces DNA damage in HCT116 cells (Tail DNA=16.1%, OTM=3.7), MCF-7 cells, HepG2 cells (Tail DNA=26.2%, OTM=13.2), Balb/c 3T3 cells (Tail DNA = 8.4%, OTM = 3.5)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

HepG2, MCF-7, HCT116, HeLa, A549, WM793, THP-1, HaCaT, Balb/c3T3 cells
Concentration:

0, 1, 10, 100 µM
Incubation Time:

72 h
Result:

Showed cytotoxic action with GI₅₀s of 12.1, 0.7, 0.8, 49.3, 9.7 µM for for HepG2, MCF-7, HCT116, HeLa, A549 cells, low toxicity towards WM793, THP-1, HaCaT, Balb/c 3T3 cells with GI₅₀s of 80.4, 62.4,98.3,40.8 µM , respectively.

Apoptosis Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

45 µM
Incubation Time:

24 h
Result:

Induced apoptosis in HepG2 cells via caspase 3, PARP1 and Bax dependent pathways.

Western Blot Analysis^[1]

Cell Line:

HCT116, MCF-7 cells
Concentration:

0.7 µM
Incubation Time:

24 h
Result:

Decreased the expression of Cdk2 protein in HCT116 and MCF-7 cells.

Cell Cycle Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

45 µM
Incubation Time:

24 h
Result:

Showed no effect on the transition of G1/S phases in HepG2 cells.

Chemical Information

CAS No. 2470015-35-9
Appearance Solid
Masse moléculaire 336.36
Formule C₁₄H₉FN₂O₃S₂
Color Light yellow to yellow
SMILES

COC(C1=C(C2=C(N1)C=CC(F)=C2)/C=C3SC(NC\3=O)=S)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : 125 mg/mL (371.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9730 mL

14.8650 mL

29.7301 mL

5 mM

0.5946 mL

2.9730 mL

5.9460 mL

10 mM

0.2973 mL

1.4865 mL

2.9730 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kryshchyshyn-Dylevych A, et al. Synthesis of novel indole-thiazolidinone hybrid structures as promising scaffold with anticancer potential. Bioorg Med Chem. 2021; 50:116453. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9730 mL	14.8650 mL	29.7301 mL	74.3251 mL
	5 mM	0.5946 mL	2.9730 mL	5.9460 mL	14.8650 mL
	10 mM	0.2973 mL	1.4865 mL	2.9730 mL	7.4325 mL
	15 mM	0.1982 mL	0.9910 mL	1.9820 mL	4.9550 mL
	20 mM	0.1487 mL	0.7433 mL	1.4865 mL	3.7163 mL
	25 mM	0.1189 mL	0.5946 mL	1.1892 mL	2.9730 mL
	30 mM	0.0991 mL	0.4955 mL	0.9910 mL	2.4775 mL
	40 mM	0.0743 mL	0.3716 mL	0.7433 mL	1.8581 mL
	50 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4865 mL
	60 mM	0.0496 mL	0.2478 mL	0.4955 mL	1.2388 mL
	80 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9291 mL
	100 mM	0.0297 mL	0.1487 mL	0.2973 mL	0.7433 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Anticancer agent 43

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Voir tous les produits spécifiques à Isoform Bcl-2 Family

Voir tous les produits spécifiques à Isoform Caspase

Voir tous les produits spécifiques à Isoform PARP

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Anticancer agent 43

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Voir tous les produits spécifiques à Isoform Bcl-2 Family

Voir tous les produits spécifiques à Isoform Caspase

Voir tous les produits spécifiques à Isoform PARP

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Anticancer agent 43 Related Classifications

HY-146548 Related Classifications